Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on June 26
June 12 2024 - 8:24AM
BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a
clinical-stage company developing innovative drug therapies for the
treatment of neurological and neurodegenerative disorders and
advanced liver disease, is pleased to invite investors to a webinar
on June 26, 2024, at 4:15 p.m. ET.
The exclusive event, hosted by RedChip Companies, will feature
Cuong Do, President and CEO of BioVie, who will share insight into
the Company’s pipeline of late-stage clinical programs targeting
unmet medical needs in neurodegeneration and liver disease.
BioVie’s lead asset, bezisterim (formerly NE3107), has
demonstrated the ability to modulate TNFα production, leading to
significant clinical improvements. Patients treated with bezisterim
experienced reduced inflammation and insulin resistance, improved
motor control and "morning on" symptoms in Parkinson's disease
(PD), enhanced cognition and function with lowered amyloid β and
p-tau levels, and better brain imaging scans in Alzheimer's disease
(AD), as well as reduced DNA methylation levels.
The Company’s strategic priorities include launching a Phase 2b
trial for Parkinson's in Fall 2024, initiating a Phase 3 trial for
Alzheimer's in mid-2025 with a new once-daily formulation of
bezisterim, continuing partnering discussions for bezisterim's
geographic rights, and commencing an ascites Phase 3 trial upon
identifying a suitable partner.
To register for the free webinar, please visit:
https://redchip.zoom.us/webinar/register/WN_xkt_hEWXST2n5mn1aDkH_w#/registration
Questions can be pre-submitted to BIVI@redchip.com or online
during the live event.
About BioVie Inc.BioVie Inc. (NASDAQ: BIVI) is
a clinical-stage company developing innovative drug therapies for
the treatment of neurological and neurodegenerative disorders and
advanced liver disease. In neurodegenerative disease, the Company’s
drug candidate bezisterim inhibits inflammatory activation of ERK
and NFκB (e.g., TNF signaling) that leads to neuroinflammation and
insulin resistance, but not their homeostatic functions (e.g.,
insulin signaling and neuron growth and survival). Both are drivers
of AD and PD. In liver disease, the Company’s Orphan drug candidate
BIV201 (continuous infusion terlipressin), with U.S. Food and Drug
Administration (“FDA”) Fast Track status, is being evaluated and
discussed with guidance received from the FDA regarding the design
of Phase 3 clinical testing of BIV201 for the treatment of ascites
due to chronic liver cirrhosis. The active agent is approved in the
U.S. and in about 40 countries for related complications of
advanced liver cirrhosis. For more information, visit
www.bioviepharma.com.
Forward-Looking StatementsThis press release
contains forward-looking statements, which may be identified by
words such as "expect," "look forward to," "anticipate" "intend,"
"plan," "believe," "seek," "estimate," "will," "project" or words
of similar meaning. Although BioVie Inc. believes such
forward-looking statements are based on reasonable assumptions, it
can give no assurance that its expectations will be attained.
Actual results may vary materially from those expressed or implied
by the statements herein due to the Company's ability to
successfully raise sufficient capital on reasonable terms or at
all, available cash on hand and contractual and statutory
limitations that could impair our ability to pay future dividends,
our ability to complete our pre-clinical or clinical studies and to
obtain approval for our product candidates, our ability to
successfully defend potential future litigation, changes in local
or national economic conditions as well as various additional
risks, many of which are now unknown and generally out of the
Company's control, and which are detailed from time to time in
reports filed by the Company with the SEC, including quarterly
reports on Form 10-Q, reports on Form 8-K and annual reports on
Form 10-K. BioVie Inc. does not undertake any duty to update any
statements contained herein (including any forward-looking
statements), except as required by law.
Contact:Dave Gentry, CEORedChip Companies,
Inc.1-407-644-4256BIVI@redchip.com
BioVie (NASDAQ:BIVI)
Historical Stock Chart
From Jul 2024 to Aug 2024
BioVie (NASDAQ:BIVI)
Historical Stock Chart
From Aug 2023 to Aug 2024